Market Summary
USD23.36+0.86
Market Closed3.82%
BLFS Stock Price
BLFS RSI Chart
BLFS Valuation
BLFS Price/Sales (Trailing)
BLFS Profitability
BLFS Fundamentals
BLFS Revenue
BLFS Earnings
Price Action
52 Week Range
12.6026.96
(Low)(High)
Last 7 days
4.9%
Last 30 days
33.0%
Last 90 days
2.5%
Trailing 12 Months
58.6%
BLFS Financial Health
BLFS Investor Care
Peers (Alternatives to BioLife Solutions)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MDT | 109.8B | 30.8B | -9.29% | -16.09% | 26.95 | 3.57 | -3.19% | -17.32% |
ISRG | 107.6B | 6.4B | 1.94% | 34.00% | 82.01 | 16.73 | 8.89% | -20.19% |
EW | 49.3B | 5.5B | -7.47% | -19.49% | 33.14 | 8.97 | 2.68% | -3.23% |
ALGN | 21.8B | 3.7B | -12.40% | 0.13% | 69.2 | 5.89 | -8.10% | -55.37% |
HOLX | 19.5B | 4.1B | -8.55% | 1.55% | 25.84 | 4.8 | -24.76% | -51.48% |
| MID-CAP | ||||||||
PEN | 11.8B | 884.6M | 9.37% | 108.01% | 1.8K | 13.39 | 13.08% | 200.12% |
NVST | 5.4B | 2.6B | -14.32% | -23.28% | 25.47 | 2.1 | 1.47% | -29.43% |
CNMD | 3.6B | 1.1B | -5.65% | 2.15% | -38.56 | 3.29 | 7.68% | -238.55% |
LIVN | 2.4B | 1.0B | -8.50% | -35.10% | -28.78 | 2.25 | 1.66% | 19.79% |
TMDX | 2.4B | 119.1M | -8.56% | 141.99% | -83.21 | 19.75 | 204.77% | 39.65% |
| SMALL-CAP | ||||||||
ESTA | 1.6B | 169.8M | -7.71% | 2.34% | -19.37 | 9.27 | 25.95% | -102.42% |
AVNS | 1.1B | 814.3M | -18.92% | -16.55% | 25.06 | 1.37 | 6.96% | 121.89% |
BLFS | 1.0B | 163.2M | 33.03% | 58.59% | -6.9 | 6.19 | 17.84% | -885.82% |
INGN | 255.0M | 369.0M | -17.13% | -57.43% | -2.84 | 0.69 | 5.00% | -353.73% |
SDC | 54.4M | 438.9M | -7.48% | -74.66% | -0.63 | 0.12 | -25.59% | -12.50% |
Financials for BioLife Solutions
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | 0.9% | 163,242,000 | 161,759,000 | 154,805,000 | 147,858,000 | 138,529,000 |
| S&GA Expenses | 7.3% | 23,150,000 | 21,570,000 | 20,361,000 | 19,149,000 | 16,876,000 |
| R&D Expenses | 2.5% | 15,169,000 | 14,798,000 | 14,205,000 | 13,999,000 | 13,616,000 |
| EBITDA | -4.9% | -104,198,000 | -99,319,000 | -28,579,000 | - | - |
| EBITDA Margin | -0.2% | -0.67 | -0.67 | -0.21 | - | - |
| Earnings Before Taxes | -4.1% | -150,784,000 | -144,827,000 | -112,837,000 | -107,190,000 | -35,573,000 |
| EBT Margin | -0.6% | -0.72 | -0.72 | -0.25 | - | - |
| Interest Expenses | 69.3% | 992,000 | 586,000 | 682,000 | 573,000 | 543,000 |
| Net Income | -4.8% | -146,453,000 | -139,805,000 | -105,322,000 | -95,286,000 | -14,856,000 |
| Net Income Margin | -5.7% | -0.67 | -0.64 | -0.10 | - | - |
| Free Cahsflow | -2.6% | -24,622,000 | -24,001,000 | -22,458,000 | - | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | -0.8% | 446 | 450 | 488 | 470 | 544 |
| Current Assets | -4.1% | 133 | 138 | 136 | 118 | 119 |
| Cash Equivalents | -1.7% | 19.00 | 19.00 | 27.00 | 24.00 | 59.00 |
| Inventory | 18.4% | 41.00 | 35.00 | 34.00 | 33.00 | 30.00 |
| Net PPE | 10.4% | 26.00 | 24.00 | 22.00 | 19.00 | 18.00 |
| Goodwill | 0% | 225 | 225 | 225 | 225 | 225 |
| Liabilities | 2.7% | 88.00 | 86.00 | 79.00 | 58.00 | 65.00 |
| Current Liabilities | 6.1% | 47.00 | 45.00 | 37.00 | 33.00 | 35.00 |
| Long Term Debt | 248.0% | 26.00 | 8.00 | 7.00 | - | - |
| LT Debt, Current | -31.1% | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 |
| LT Debt, Non Current | -0.4% | 24.00 | 24.00 | 24.00 | 6.00 | 6.00 |
| Shareholder's Equity | -1.7% | 358 | 364 | 408 | 412 | 479 |
| Retained Earnings | -5.6% | -260 | -246 | -194 | -184 | -112 |
| Additional Paid-In Capital | 1.2% | 619 | 612 | 604 | 598 | 591 |
| Shares Outstanding | 1.1% | 43.00 | 43.00 | 43.00 | 43.00 | 42.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | 61.4% | -3.28 | -8.49 | -17.12 | -16.53 | -14.34 |
| Share Based Compensation | 7.8% | 27.00 | 25.00 | 23.00 | 21.00 | 18.00 |
| Cashflow From Investing | 8.9% | -52.92 | -58.12 | -45.76 | -31.89 | -11.03 |
| Cashflow From Financing | -2.3% | 16.00 | 16.00 | 15.00 | -3.63 | -4.17 |
Risks for BLFS
What is the probability of a big loss on BLFS?
97.7%
Probability that BioLife Solutions stock will be more than 20% underwater in next one year
86.2%
Probability that BioLife Solutions stock will be more than 30% underwater in next one year.
63.1%
Probability that BioLife Solutions stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BLFS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if BioLife Solutions was unfortunately bought at previous high price.
Drawdowns
Returns for BLFS
Cumulative Returns on BLFS
16.6%
10-Year Cumulative Returns
47%
7-Year Cumulative Returns
16.9%
5-Year Cumulative Returns
12.4%
3-Year Cumulative Returns
What are the long-term rolling returns for BLFS?
FIve years rolling returns for BioLife Solutions.
Annualized Returns
Which funds bought or sold BLFS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -14.7 | 397,895 | 20,968,900 | 0.01% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | added | 2.55 | 1,451,000 | 7,884,000 | 0.01% |
2023-05-18 | JPMORGAN CHASE & CO | added | 0.31 | 1,462,000 | 8,815,000 | -% |
2023-05-17 | Thrivent Financial for Lutherans | added | 2.11 | 1,375,000 | 7,614,000 | 0.02% |
2023-05-16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 358,658 | 358,658 | -% |
2023-05-16 | Meros Investment Management, LP | added | 4.00 | 955,704 | 4,888,700 | 2.78% |
2023-05-16 | FRED ALGER MANAGEMENT, LLC | reduced | -2.66 | 5,875,300 | 41,873,400 | 0.22% |
2023-05-16 | Baker Avenue Asset Management, LP | unchanged | - | 3,578 | 21,924 | -% |
2023-05-16 | Rockefeller Capital Management L.P. | sold off | -100 | -90,000 | - | -% |
2023-05-15 | KENFARB & CO. | unchanged | - | 17,800 | 108,750 | 0.10% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
BioLife Solutions News
Schedule 13G FIlings of BioLife Solutions
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 5.77% | 2,466,931 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 12.8% | 5,477,126 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 12.8% | 5,477,126 | SC 13G/A | |
| Jan 11, 2023 | millennium management llc | 1.6% | 670,202 | SC 13G/A | |
| Jul 08, 2022 | blackrock inc. | 11.5% | 4,893,203 | SC 13G | |
| Jun 22, 2022 | millennium management llc | 5.1% | 2,166,344 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 5.16% | 2,147,258 | SC 13G | |
| Feb 01, 2022 | blackrock inc. | 8.8% | 3,655,057 | SC 13G/A | |
| Nov 01, 2021 | villiger walter | 4.86% | 1,979,226 | SC 13D/A | |
| Sep 09, 2021 | blackrock inc. | 11.1% | 4,528,723 | SC 13G |
Recent SEC filings of BioLife Solutions
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 25, 2023 | 4 | Insider Trading | |
| May 23, 2023 | 4 | Insider Trading | |
| May 19, 2023 | 4/A | Insider Trading | |
| May 19, 2023 | 8-K | Current Report | |
| May 18, 2023 | 4 | Insider Trading | |
| May 17, 2023 | 4 | Insider Trading | |
| May 17, 2023 | 4 | Insider Trading | |
| May 17, 2023 | 4 | Insider Trading | |
| May 17, 2023 | 4 | Insider Trading | |
| May 17, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for BLFS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-25 | Mathew Aby J. | acquired | 20,600 | 2.06 | 10,000 | evp & chief scientific officer |
2023-05-25 | Mathew Aby J. | sold | -223,300 | 22.33 | -10,000 | evp & chief scientific officer |
2023-05-24 | Mathew Aby J. | acquired | 20,600 | 2.06 | 10,000 | evp & chief scientific officer |
2023-05-24 | Mathew Aby J. | sold | -221,400 | 22.14 | -10,000 | evp & chief scientific officer |
2023-05-22 | Casdin Partners Master Fund, L.P. | bought | 545,790 | 21.8552 | 24,973 | - |
2023-05-19 | Casdin Partners Master Fund, L.P. | bought | 1,127,430 | 22.5486 | 50,000 | - |
2023-05-18 | Casdin Partners Master Fund, L.P. | bought | 652,692 | 21.7564 | 30,000 | - |
2023-05-17 | Rice Michael | sold | -701,326 | 21.04 | -33,333 | ceo |
2023-05-17 | Casdin Partners Master Fund, L.P. | bought | 639,446 | 21.2957 | 30,027 | - |
2023-05-16 | Wichterman Troy | sold | -2,659 | 19.41 | -137 | chief financial officer |
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
BLFS Income Statement
2023-03-31Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Revenue | $ 37,703 | $ 36,220 |
| Costs and operating expenses: | ||
| General and administrative | 14,842 | 11,530 |
| Sales and marketing | 6,471 | 4,891 |
| Research and development | 4,152 | 3,781 |
| Intangible asset amortization | 1,459 | 2,863 |
| Acquisition costs | 0 | 11 |
| Change in fair value of contingent consideration | 720 | (3,335) |
| Total operating expenses | 51,308 | 44,187 |
| Operating loss | (13,605) | (7,967) |
| Other expense: | ||
| Interest expense, net | (411) | (184) |
| Other income | 394 | 131 |
| Total other expense, net | (17) | (53) |
| Loss before income tax (expense) benefit | (13,622) | (8,020) |
| Income tax (expense) benefit | (92) | 599 |
| Net loss | (13,714) | (7,421) |
| Net loss attributable to common shareholders: | ||
| Basic and Diluted | $ (13,714) | $ (7,421) |
| Basic and Diluted (in dollars per share) | $ (0.32) | $ (0.18) |
| Weighted average shares used to compute loss per share attributable to common shareholders: | ||
| Basic and Diluted (in shares) | 43,027,612 | 42,014,055 |
| Product [Member] | ||
| Revenue | $ 31,593 | $ 30,388 |
| Costs and operating expenses: | ||
| Cost of goods and services | 18,397 | 20,384 |
| Service Revenue [Member] | ||
| Revenue | 4,471 | 3,090 |
| Costs and operating expenses: | ||
| Cost of goods and services | 3,891 | 2,145 |
| Rental Revenue [Member] | ||
| Revenue | 1,639 | 2,742 |
| Costs and operating expenses: | ||
| Cost of goods and services | $ 1,376 | $ 1,917 |
BLFS Balance Sheet
2023-03-31Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 19,105 | $ 19,442 |
| Restricted cash | 31 | 31 |
| Available-for-sale securities, current portion | 35,780 | 43,260 |
| Accounts receivable, trade, net of allowance for doubtful accounts of $956 and $739 as of March 31, 2023 and December 31, 2022, respectively | 30,343 | 33,936 |
| Inventories | 41,329 | 34,904 |
| Prepaid expenses and other current assets | 6,201 | 6,879 |
| Total current assets | 132,789 | 138,452 |
| Assets held for rent, net | 9,005 | 9,064 |
| Property and equipment, net | 26,100 | 23,638 |
| Operating lease right-of-use assets, net | 15,592 | 15,292 |
| Financing lease right-of-use assets, net | 242 | 272 |
| Long-term deposits and other assets | 284 | 281 |
| Available-for-sale securities, long-term | 2,019 | 1,332 |
| Equity investments | 5,069 | 5,069 |
| Total intangible assets, net | 30,629 | 32,088 |
| Goodwill | 224,741 | 224,741 |
| Total assets | 446,470 | 450,229 |
| Current liabilities: | ||
| Accounts payable | 15,525 | 15,367 |
| Accrued expenses and other current liabilities | 10,701 | 9,782 |
| Sales taxes payable | 4,585 | 4,151 |
| Warranty liability | 8,895 | 8,312 |
| Lease liabilities, operating, current portion | 2,906 | 2,860 |
| Lease liabilities, financing, current portion | 161 | 158 |
| Debt, current portion | 1,250 | 1,814 |
| Contingent consideration, current portion | 3,296 | 2,138 |
| Total current liabilities | 47,319 | 44,582 |
| Contingent consideration, long-term | 1,880 | 2,318 |
| Lease liabilities, operating, long-term | 15,114 | 14,962 |
| Lease liabilities, financing, long-term | 95 | 126 |
| Debt, long-term | 23,692 | 23,793 |
| Deferred tax liabilities | 263 | 250 |
| Other long-term liabilities | 0 | 10 |
| Total liabilities | 88,363 | 86,041 |
| Commitments and contingencies (Note 12) | ||
| Shareholders’ equity: | ||
| Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.001 par value; 150,000,000 shares authorized, 43,289,969 and 42,832,231 shares issued and outstanding, respectively, as of March 31, 2023 and December 31, 2022 | 43 | 43 |
| Additional paid-in capital | 619,227 | 611,739 |
| Accumulated other comprehensive loss, net of taxes | (534) | (679) |
| Accumulated deficit | (260,629) | (246,915) |
| Total shareholders’ equity | 358,107 | 364,188 |
| Total liabilities and shareholders’ equity | $ 446,470 | $ 450,229 |